A bill to require persons who undertake Federally funded research and development of drugs to enter into reasonable pricing agreements with the Secretary of Health and Human Services.

referredUnited States· United States Congress· EN

Introduced

31 July 2017

Last action

—

Status

Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

Summary

This bill prohibits federal agencies and nonprofit entities that conduct federally funded health care research from providing a patent for a drug based on such research until the entity receiving the patent enters into a reasonable pricing agreement with the Department of Health and Human Services.

This text is taken from the official record. PoliticalRepo does not editorialize.

Timeline

No timeline events have been ingested for this record yet.

Votes

No vote records are attached yet.

Versions

No version snapshots stored. Document URLs remain at the source.

Documents

3 official files

Introduced in Senate (text)

View file Download file

Introduced in Senate (text)
Introduced in Senate · EN · 31 July 2017
View Download Open at official source
Introduced in Senate (PDF)
Introduced in Senate · EN · 31 July 2017
View Download Open at official source
Introduced in Senate
summary · EN · 31 July 2017
Open at official source

Related records

No cross-record relationships stored yet.

Sources

PoliticalRepo is an index and interpretation layer, not the authoritative legal source.

Official source: https://www.congress.gov/bill/115th-congress/senate-bill/1681
Open data entity: https://api.congress.gov/v3/bill/115/s/1681